Navigation Links
First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries

(maximum intima media thickness (IMT) >1.2 and <3.5 mm). METEOR used B-mode ultrasound imaging to assess and measure change in mean maximum IMT of 12 vessel sites in the carotid artery. The study evaluated low risk subjects not indicated for statin therapy to permit inclusion of a comparative placebo arm.

Currently, CRESTOR is indicated for the treatment of lipid disorders. The results from the METEOR study, supported by data from the ASTEROID study and including the ORION trial, formed the basis of the atherosclerosis regulatory submissions filed in the European Union and the United States in January 2007. These submissions seek to expand the use of CRESTOR to include the treatment of atherosclerosis with the purpose of impacting the progression of the disease in patients in whom lipid-lowering therapy is indicated.

These new results from METEOR add to the wealth of CRESTOR efficacy data from its extensive GALAXY clinical trials programme, designed to address important unanswered questions in statin research and to investigate the impact of CRESTOR on cardiovascular risk reduction and patient outcomes. Currently, more than 63,000 patients have been recruited from 55 countries worldwide to participate in the GALAXY Programme.

CRESTOR has now received regulatory approvals in over 90 countries across five continents. Over 9 million patients have been prescribed CRESTOR worldwide. Data from clinical trials and marketed use shows that the safety profile for CRESTOR is in line with other marketed statins. Annual sales for Crestor exceeded $2 billion for the first time in 2006.

The 40 mg dose is the highest registered dose of CRESTOR. CRESTOR should be used according to the prescribing information, which contains recommendations for initiating and titrating therapy according to the individual patient profile. In most countries, the usual recommended starting dose of CRESTOR is 10mg. The 40mg dose should only be used in patients who have not ac
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:5/24/2013)... May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... participate in the Deutsche Bank Health Care Conference to ... Hotel.  Mr. Adrian Adams , Chief ... overview of the Company and its product pipeline at ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The ...
(Date:5/24/2013)... May 24, 2013 The potential ... systemic delivery of therapeutic agents has been receiving undeniable ... delivery showing significant promise. The crucial formulation considerations for ... device play a major role in the efficiency of ... the development of new formulation techniques and devices in ...
(Date:5/23/2013)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... 2011 With the support of Key Opinion Leaders ... the time and attention of KOLs is intensifying. But ... landscape for creating and maintaining KOL and physician relationships. ... KOL landscape, Best Practices, LLC has published an updated ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... of President, HealthTronics Inc., effective Aug. 29, 2011. HealthTronics, ... urological products and services based in Austin, Texas. ... HealthTronics Group President James Whittenburg, who is staying through ...
Cached Medicine Technology:Pharma Medical Science Liaison Outreach Shifting Away from Traditional Company Sales Regions 2Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President 2Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President 3
(Date:5/25/2013)... New York, NY (PRWEB) May 25, 2013 Country ... was Jason Aldean's opening act in 2012. Due to overwhelming ... countless venues during 2013. , Luke Bryan has written ... a songwriter nearly a decade ago back in the mid-2000 era. ... Billy Currington and Travis Tritt. , When Luke was 14, ...
(Date:5/25/2013)... 25, 2013 According to an article in ... a Feeling,” nearly 30 million Americans tan indoors each year ... despite knowing the health risks. New research suggests ... addictive effect on the brains of some tanners (Go to ... article so I can’t say that I fully support this ...
(Date:5/25/2013)... It's not astonishing that holidays are amongst the most ... from family, friends and co-workers. Between the parties to ... their parents can afford, parties to arrange, and so ... anniversaries and it seems like an eternal cycle of ... and income can’t catch up to the expenses of ...
(Date:5/25/2013)... May 25, 2013 Life science and ... used to detect and create a new substance with ... and are also known as biotechnology reagents. Such reagents ... and education. , This market is driven by factors ... the field of therapeutics, growth in research and rapid ...
(Date:5/25/2013)... New York, New York (PRWEB) May 25, 2013 ... a federal multidistrict litigation underway in U.S. District Court, ... Liebhard LLP reports. According to a Case Management ... procedures that govern the filing of contested motions in ... for filing those motions. (In re: Actos Product Liability ...
Breaking Medicine News(10 mins):Health News:Luke Bryan Tickets: Prices Slashed on Luke Bryan Tickets in Raleigh, Bethel, Camden, Peoria, Nashville, Hartford, Chicago, Boston, Atlanta, Indianapolis & SaratogaSprings 2Health News:Sun Damage – Are UV Rays Addictive? 2Health News:TheBeautyPlace.com Debuts Their Brand New Beauty Kits 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3
... 17 Carla Bluhm, a developmental psychologist and visiting assistant ... class of 2007, have recently completed a book on the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080220/DC14623 ) , ... Identity and the New Science of Face Transplants" begins with ...
... for Physicians , , VOORHEES, ... infection (CDI) in geriatric and pediatric populations ... in CDI incidence in many age groups, healthcare professionals need ... patient populations. , , To ...
... Dec. 17 minSURG Corporation, along with,its ... NuFix,Inc. ("NuFix"), along with its affiliate Nutech ... settlement of the lawsuits styled Orthopedic,Development Corporation ... Inc., Kenneth Horton and Todd Gilbert, Case ...
... 17 Michelle Aguilar may be the latest,"Biggest Loser" but she ... that when working out hard, it,s important to include the nutrients ... a day provide.,Aguilar is the latest person to lend her upper ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081217/AQW560 ) , ...
... Labs announces the,availability of its advanced ocular nutrition line ... CVS Pharmacy stores ( www.cvs.com ),nationwide. , ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081217/CLW029-b ... marks the first time EyeScience Macular Health Formula(TM) and,EyeScience ...
... improve cognitive impairment, study says , , WEDNESDAY, Dec. ... Alzheimer,s patients, cognitive symptoms are also a safe ... such as aggression, wandering and paranoia, according to ... that examined the effectiveness of three popular cholinesterase ...
Cached Medicine News:Health News:Psychology of Face Transplants is Subject of New Book by Allegheny College Professor 2Health News:Current Concepts in Clostridium difficile Infection: A Focus on Geriatric and Pediatric Patients 2Health News:EyeScience's New Ocular Nutrition Supplements Available at CVS Stores 2Health News:Alzheimer's Drugs Also Treat Behavioral, Psych Problems 2
... a whole blood control for evaluating the ... measure automated blood cell counts in patient ... RBC and WBC values for the Abbott ... LH750/LH 755 (levels 2 and 3 only) ...
iSleep 20i is an advanced high performance CPAP with outstanding self-adjusting i‑technology....
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: